HER2-positive breast cancer with brain metastasis, long responder to lapatinib therapy

HER2-positive breast cancer with brain metastasis, long responder to lapatinib therapy

We report the case of a 45-year-old patient diagnosed, after four years from the initial diagnosis of infiltrating ductal carcinoma, with lymph node, hepatic, pulmonary and bone diseases deriving from HER2-positive breast cancer. While the association docetaxel + trastuzumab led to a partial respons...

Bibliografske podrobnosti
Glavni avtor:	Chiara Saggia
Format:	Article
Jezik:	English
Izdano:	AboutScience Srl 2018-06-01
Serija:	AboutOpen
Teme:	Lapatinib Metastatic breast cancer Brain metastasis HER2 Long-term survival
Online dostop:	https://journals.aboutscience.eu/index.php/aboutopen/article/view/160

Podobne knjige/članki

HER2-positive breast cancer with brain metastasis: long-lasting response after lapatinib treatment
od: Alessia D'Alonzo, et al.
Izdano: (2018-06-01)

Lunga sopravvivenza di una paziente con carcinoma mammario HER2-positivo, in trattamento con lapatinib
od: Anna Gambaro
Izdano: (2017-12-01)

Good control of diffuse brain metastasis with lapatinib plus capecitabine in a patient with HER2-positive breast cancer
od: Giovanni Faggioni
Izdano: (2018-06-01)

Sopravvivenza a lungo termine in paziente trattata con lapatinib e capecitabina
od: Carlo Mulas
Izdano: (2017-12-01)

Long-term survival in a patient with metastatic HER2+ breast cancer undergoing lapatinib-based therapy for 6 years
od: Salvatore Turano, et al.
Izdano: (2018-09-01)

Efficacy of second-line treatment with capecitabine and lapatinib in HER2-positive mammary neoplasia, with encephalic metastasis, after first-line therapy with dual anti-HER2 block
od: Tea Zeppola
Izdano: (2018-06-01)

Systemic control and encephalic response with lapatinib plus capecitabine as second-line therapy in HER2-positive, metastatic breast cancer
od: Raffaele Ardito, et al.
Izdano: (2018-09-01)

Paziente con carcinoma mammario oligometastatico HER2-positivo, lungosopravvivente in trattamento con lapatinib/ capecitabina dopo resezione e termoablazione polmonare
od: Gennaro Gadaleta-Caldarola
Izdano: (2017-12-01)

Long-lasting response with lapatinib treatment: a case report
od: Andrea Milani, et al.
Izdano: (2018-09-01)

Long-term Survival after Lapatinib Rechallenge in Isolated Brain Metastasis of HER2-positive Breast Cancer
od: Bülent Karagöz, et al.
Izdano: (2015-01-01)

Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea
od: Ro Jungsil, et al.
Izdano: (2012-07-01)

Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
od: Daniela Cianniello, et al.
Izdano: (2018-06-01)

Toxicity management and efficacy of lapatinib-capecitabine in elderly patient with lymph node metastasis from HER2-positive occult mammary carcinoma
od: Giuseppe Quarta, et al.
Izdano: (2018-06-01)

Lunga risposta al trattamento di II linea con lapatinib in paziente con secondarismi encefalici da carcinoma mammario HER2-positivo
od: Tiziana Prochilo
Izdano: (2017-12-01)

Response to Lapatinib-Capecitabine combination in a young patient with recurrent HER2-positive breast cancer refractory to two lines of therapy with anti-HER2 drugs
od: Clementina Savastano, et al.
Izdano: (2018-10-01)

Lunga sopravvivenza in paziente con carcinoma mammario oligometastatico all’encefalo, trattata con lapatinib
od: Elena Orlandi, et al.
Izdano: (2017-12-01)

Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use
od: C. García-Muñoz, et al.
Izdano: (2014-03-01)

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study
od: Yizhao Xie, et al.
Izdano: (2020-05-01)

Lapatinib and chronic renal insufficiency
od: Luca Moscetti
Izdano: (2018-03-01)

Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease
od: Lauren Ogawa, et al.
Izdano: (2018-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
od: Gerald M. Higa
Izdano: (2011-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
od: Gerald M. Higa
Izdano: (2011-12-01)

The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
od: D. J Ouyang, et al.
Izdano: (2021-08-01)

Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months' Remission with Lapatinib plus Capecitabine
od: Audrey Mailliez, et al.
Izdano: (2014-08-01)

Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated With A Combination of Lapatinib and Capecitabine
od: İzzet Doğan, et al.
Izdano: (2023-04-01)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
od: Thibaut Sanglier, et al.
Izdano: (2023-06-01)

Efficacy of lapatinib-capecitabine combination in a patient with multiple metastasis from HER2-positive breast cancer
od: Maria Moritti, et al.
Izdano: (2018-06-01)

Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study
od: Kazuki Nozawa, et al.
Izdano: (2022-09-01)

Efficacia duratura e ottima tollerabilità di lapatinib associato a capecitabina metronomica in due pazienti con carcinoma mammario HER2-positivo
od: Armando Orlandi, et al.
Izdano: (2017-12-01)

Efficacia della combinazione lapatinib-capecitabina in una paziente con carcinoma mammario HER2-positivo metastatico e con resistenza primaria a due linee di terapia con agenti anti-HER2
od: Claudio Vernieri, et al.
Izdano: (2017-12-01)

Lapatinib and capecitabine efficacy at systemic and encephalic level in a patient progressed after dual block of HER2 by trastuzumab and pertuzumab and after T-DM1
od: Andrea Fontana
Izdano: (2018-06-01)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
od: Min Ye, et al.
Izdano: (2021-07-01)

Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
od: Fabien Moinard-Butot, et al.
Izdano: (2022-06-01)

Long-term survival in a young woman with recurrent HER2-positive breast cancer.
od: Gianluca Cotroneo
Izdano: (2018-06-01)

Lapatinib and capecitabine as third-line therapy in young woman with advanced breast cancer
od: Michela Donadio
Izdano: (2018-06-01)

Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib
od: A. Geneste, et al.
Izdano: (2020-08-01)

Budget impact analysis of the use of lapatinib in the treatment of breast cancer in Italy
od: Francesco Bamfi, et al.
Izdano: (2009-03-01)

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
od: Ye Yuan, et al.
Izdano: (2022-12-01)

Feedback Activation of STAT3 Confers Resistance of HER2-positive Breast Cancer Cells to Lapatinib
od: HU Xiaohong, et al.
Izdano: (2019-04-01)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
od: E. Von Cheong, et al.
Izdano: (2021-04-01)